1D09C3, an mAb specific for MHC-II

Simple item page
dc.contributor.authorZola, H.
dc.contributor.authorBeare, A.
dc.date.issued2008
dc.description.abstractGPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.
dc.description.statementofresponsibilityH Zola and A Beare
dc.description.urihttp://www.biomedcentral.com/1464-8431/10/68/abstract
dc.identifier.citationCurrent Opinion in Molecular Therapeutics, 2008; 10(1):68-74
dc.identifier.issn1464-8431
dc.identifier.issn2040-3445
dc.identifier.urihttp://hdl.handle.net/2440/53599
dc.language.isoen
dc.publisherPharmapress Ltd
dc.subjectAnimals
dc.subjectHumans
dc.subjectAntibodies, Monoclonal
dc.subjectHistocompatibility Antigens Class II
dc.subjectDrug Evaluation, Preclinical
dc.subjectAntibody Specificity
dc.subjectStructure-Activity Relationship
dc.subjectClinical Trials as Topic
dc.subjectPatents as Topic
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectContraindications
dc.title1D09C3, an mAb specific for MHC-II
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Paediatrics publications